Drug Approval | July 24, 2023
Aurobindo Pharma gets 3 observations from USFDA for Unit 3 at Bachupally Village
Aurobindo will respond to the US FDA within the stipulated timelines
Aurobindo will respond to the US FDA within the stipulated timelines
This product would be manufactured at Lupin's Nagpur facility in India
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
CMOs showed an increasing reluctance to take on debt in 2022
Subscribe To Our Newsletter & Stay Updated
